New analyses from GARFIELD-AF (Global Anticoagulant Registry in the Field–Atrial Fibrillation) will be presented at the 2015 ESC Congress (29 August–2 September, London, UK).
Real-world insights into current therapy choices for patients with newly diagnosed atrial fibrillation will provide physicians with a better understanding of how the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) is impacting care and clinical outcomes generally as well as within distinctive populations.
Real-world data from over 40,000 patients will be presented at a satellite symposium, and at one platform and three poster presentations.
The satellite symposium, titled “Anticoagulation and atrial fibrillation (AF): real life data from the GARFIELD-AF Registry” will feature an expert faculty discussing the design of GARFIELD-AF in the context of the value that registries bring to clinical research. They will also present the latest data on treatment and outcomes in the global population and in specific patient subgroups.
The Oral session, “Vitamin K antagonist control in Eastern and Southeastern Asia” will include a comparison of the distribution of international normalised ratio values in patients receiving a vitamin K antagonist for newly diagnosed atrial fibrillation in countries in Eastern and Southeastern Asia with that for patients in other countries represented in GARFIELD-AF.
The three poster presentations will look at patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe, evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation and stroke, and major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease.
These presentations will enhance the breadth and depth of the understanding of the importance of stroke prevention in atrial fibrillation, and ultimately help to develop strategies for improving patient outcomes worldwide. Baseline data for more than 40,000 patients indicates that, currently, the management of many newly diagnosed patients is not consistent with evidence-based guidelines, with patients inappropriately receiving anticoagulants or being under-treated with anticoagulants, despite the increasing availability of NOACs. The impact of sub-optimal management strategies on patient outcomes suggests a cause for ongoing concern.